Substituted reverse pyrimidine bmi-1 inhibitors
AssigneePTC Therapeutics, Inc.
InventorsChang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
Life of this patent
Estimating the term…
Abstract
Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
Claims18
1-20. (canceled)
A compound, wherein the compound is 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.